Bachem, a leading Swiss manufacturer of peptides and oligonucleotides, reported robust financial results for the first half of 2025 and unveiled plans to invest USD 460 million over the year to expand its global manufacturing footprint.
Bachem | 29/07/2025 | By Darshana | 233
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy